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Study of the epidemiologic trends in meningococcal dis-
ease is important in understanding infection dynamics and
developing timely and appropriate public health interventions.
We studied surveillance data from the New York City
Department of Health and Mental Hygiene, which showed that
during 1989–2000 a decrease occurred in both the proportion of
patients with serogroup B infection (from 28% to 13% of report-
ed cases; p<0.01) and the rate of serogroup B infection (from
0.25/100,000 to 0.08/100,000; p<0.01). We also noted an
increased proportion (from 3% to 39%; p<0.01) and rate of
serogroup Y infection (from 0.02/100,000 to 0.23/100,000;
p<0.01). Median patient age increased (from 15 to 30 years;
p<0.01). The case-fatality rate for the period was 17%. As more
effective meningococcal vaccines become available, recom-
mendations for their use in nonepidemic settings should consid-
er current epidemiologic trends, particularly changes in age and
serogroup distribution of meningococcal infections. 
M
eningococcal disease is a broad term used to describe the
different clinical syndromes resulting from Neisseria
meningitidis infection. Its two major clinical illnesses, menin-
gitis and meningococcemia (i.e., sepsis caused by meningococ-
cal infection), occur more often as sporadic cases, but occa-
sional outbreaks are an important cause of illness and death
worldwide. 
In the United States, a substantial proportion of cases of
meningitis and sepsis are caused by N. meningitidis (1). The
incidence rate of meningococcal disease in the United States is
estimated to be 0.7–1.4/100,000 population, and the case-fatal-
ity rate (CFR) is approximately 10% (2,3). Both the incidence
rate and CFR have been relatively constant, with no major
changes observed in the past decade (2).
Serogroups B and C are the most common strains found in
the United States; however, increased rates of infection from
serogroup Y were observed in the 1990s (2,3). Changes in the
age distribution of those infected have also been noted, and the
conventional concept that meningococcal disease predominate-
ly affects infants and young children should be revised because
the median age of meningococcal disease case-patients has
increased (2).
We describe the epidemiology of meningococcal disease
in New York City from January 1989 to December 2000 with
an emphasis on the trends of serogroup incidence, age, and
fatality rates. The hypotheses tested were: Consistent with the
trends in the epidemiology of meningococcal disease in the
United States, the incidence of serogroup Y infection in New
York City is increasing, the median age of patients is increas-
ing, and the CFR is comparable to national figures.
Methods
The study included New York City residents who met the
case definition for confirmed or probable meningococcal dis-
ease, as defined by the Centers for Disease Control and
Prevention and the Council of State and Territorial
Epidemiologists. Inclusion in the study as a confirmed case
required a clinically compatible course with the isolation of N.
meningitidis from a sterile site (e.g., blood, cerebrospinal fluid,
joint fluid, or pleural fluid); inclusion as a probable case
required a positive antigen test from cerebrospinal fluid or clin-
ically described purpura fulminans (4). The period of study was
January 1989–December 2000. 
We obtained the meningococcal disease cases from the
New York City Department of Health and Mental Hygiene
(referred to hereafter as NYC Department of Health) surveil-
lance database of reportable diseases. Meningococcal disease is
a national reportable disease; in New York City, all cases are
required by health code to be reported to the NYC Department
of Health. Physician reports, investigation forms, and laborato-
ry reports were reviewed for all the meningococcal disease
patients included in the NYC Department of Health database.
All cases with evidence of the study criteria were included.
Data on meningococcal disease used in this study were collect-
ed through routine passive surveillance, and serogroup identifi-
cation was performed by the NYC Department of Health Public
Health Laboratory. Antibiotic resistance profiles and pulsed-
field gel electrophoresis results were available only for a sub-
set of isolates after 1999 and are not included in this report.
Archival data and population estimates (before 1989) were
obtained from New York City Vital Statistics Annual Summary
reports.
The database contained information on each cast-patient’s
age, sex, race, ethnicity, borough of residence, and death.
Information on race and ethnicity was incomplete and therefore
was not analyzed. When death information was missing,
patient identifiers were submitted to the New York City Vital
Records and Registry for a death certificate search, which was
accomplished by searching by name and International
Classification of Diseases (ICD) code. Using name search, staff
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used visual inspection to search the New York City death cer-
tificates, looking for the name of each patient with an unknown
cause of death in the 1-month period after the date of onset of
the disease. We also conducted a search using the ICD codes
that correspond to meningococcal disease (ICD-9 036.0–036.9
and ICD-10 A39.0–A39.9); the search identified all death cer-
tificates from 1989 to 2001 that included these codes. We used
the information found through this second search method if the
death certificate referred to a patient already in the database
with an unknown outcome. We did not include death certifi-
cates with meningococcal disease ICD codes that referred to
patients not previously included in the database (i.e., they had
not been reported to the NYC Department of Health as having
meningococcal disease) because of the lack of data to confirm
the diagnosis. Patients whose names did not appear in the death
certificate search file were considered survivors in the CFR cal-
culation. This study was based on electronic data and surveil-
lance records; we ensured confidentiality by excluding all iden-
tifying information from the active analysis database.
Statistical Methods
Incidence rates were calculated by using 1990 and 2000
population files from the U.S. Census Bureau. We used the
Pearson chi-square test or Fisher exact test to assess the statis-
tical significance of categorical variables and the Kruskal-
Wallis test to assess continuous variables. 
Time trend analysis was performed to detect an association
between time (e.g., year or year group) and response variables
(e.g., serogroup and outcome). We used the Spearman correla-
tion test and chi-square test for linear trends to assess statistical
significance. Logistic regression models were built to provide
coefficients for significant trends.
Independence can be assumed from the data because most
cases were sporadic throughout the study period; we consid-
ered the vast majority of cases to be unrelated. In addition, no
patient had more than one episode of the disease during the
study period, and the analyses were performed with the patients
grouped into 3-year intervals to minimize any existing correla-
tion between sequential years (5). The SPSS (SPSS Inc.,
Chicago, IL) statistical software package and Epi Info 2000
(Centers for Disease Control and Prevention, Atlanta, GA) soft-
ware were used to perform the statistical calculations. 
Results
Among New York City residents, 615 cases of meningo-
coccal disease were reported to the NYC Department of Health
from January 1989 to December 2000, with an average annual
incidence of 0.67/100,000; of cases reported, 582 cases (95%)
were confirmed and 33 cases (5%) were included as probable.
Meningococcemia occurred in 54% of the cases, meningitis in
44%, and pneumonia, septic arthritis or other sterile site infec-
tions in 2%. All cases were considered to be sporadic except for
two case-patients in 1997 who were contacts of a primary case-
patient in a juvenile detention center resident and one culture-
negative case-patient in 2000 who was linked to a subsequent
confirmed case-patient by household contact.
For the period 1989–2000, the meningococcal disease rate
decreased by 33%, compared to the period 1953–1988, and
declined by 90%, compared to the period 1905–1952 (Table 1).
During the period under study, a 69% reduction occurred at the
beginning of the 1990s, with the rates dropping from 1.19 per
100,000 population in 1989 to 0.37 per 100,000 population in
1992 (chi square for trend = 9.1; p<0.01). Since then, rates have
increased slightly and remained relatively constant (Table 1).
When children <1 year of age are excluded, the declining trend
in incidence is no longer statistically significant (chi square for
trend = 2.4; p<0.12). 
When stratified by borough of patient residence, the aver-
age incidence rates were highest in the Bronx (0.88/100,000)
and Manhattan (0.81/100,000) and lowest in Brooklyn
(0.65/100,000), Staten Island (0.65/100,000), and Queens
(0.55/100,000). However, the differences between boroughs
were not statistically significant (chi square = 1.4; df = 4;
p = 0.23). Rates by United Hospital Fund neighborhoods
ranged from 0.23 to 1.08 per 100,000. The highest rates
occurred in two northern Manhattan and one central Bronx
neighborhoods; the lowest rates were all in Queens.
The highest average annual incidence rate was observed
among patients <1 year of age (8.49/100,000), with substantial-
ly lower rates observed for older age groups (Table 2). Astatis-
tically significant declining trend for the age groups of <1 years
of age (chi square for trend = 21.5; p<0.01) and 1–4 years of
age (chi square for trend =14.3; p<0.01) was seen over the four
3-year groups. No other decrease or increase in age-specific
incidence trends was statistically significant. The proportion of
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Table 1. Rates of meningococcal disease, New York City,  
1905–2000 
Yr group or yr  Cases
a  Annual rate/100,000 
1905–1916  7,038  12.3 
1917–1928  3,715  5.44 
1929–1940  3,844  4.29 
1941–1952  4,505  4.75 
1953–1964  1,007  1.08 
1965–1976  707  0.75 
1977–1988  986  1.16 
1989  87  1.19 
1990  79  1.08 
1991  30  0.41 
1992  27  0.37 
1993  40  0.55 
1994  42  0.57 
1995  54  0.73 
1996  59  0.80 
1997  54  0.73 
1998  35  0.47 
1999  59  0.79 
2000  50  0.62 
1989–2000  615  0.67 
aBefore 1945, meningococcal disease was classified as cerebrospinal fever or epidemic 
spinal meningitis. cases occurring in young children (<5 years of age) decreased
from 39% in 1989–1991 to 17% in 1998–2000.
The overall median age of the patients with meningococ-
cal disease was 22 years; stratification by year group showed
that median age has increased from 15 years of age in
1989–1991 to 30 years of age in 1998–2000 (Kruskal-Wallis
test; chi square = 20.0; df =3; p<0.01). To assess the effect of
changes in serogroup on the median age, serogroups B, C, Y,
and unknown were sequentially excluded from the computation
of median age. Only the removal of serogroup Y resulted in a
loss of statistical significance of the trend in median age
(Kruskal-Wallis test; chi square = 7.6; df=3; p=0.06). 
Overall incidence rates were higher for males
(0.73/100,000) than females (0.61/100,000; relative risk [RR] =
1.19; 95% confidence interval [CI] 1.02 to 1.40). However,
CFR was higher (20.1% vs. 13.9%; RR=1.45; 95% CI 1.02 to
2.07) for females. No statistically significant differences were
found in gender-specific incidence rate by age category.
Serogroup was determined for 423 (72%) of 582 culture-
positive cases. From 1989 to 2000, serogroups B, Y, and C
were the most commonly identified serogroups (32% [n=137],
28% [n=119], and 27% [n=112], respectively) of the cases for
which a serogroup was known. Serogroup W135 constituted
7% (n=28); nongroupable, 3% (n=13); A, 2% (n=9); and other
serogroups, 1% (n=5) of the isolates. The median age of the
case-patients differed by serogroup, with the highest median
age for nongroupable (48 years of age), followed by other (43
years of age), Y (37 years of age), A (34 years of age), W (27
years of age), C (23 years of age), and B (11 years of age). 
Incidence rates for serogroup B infections declined in all
age groups with the largest decline in the <1-year and 1–4-year
age groups in 1989–2000. Serogroup Y incidence rates
increased twofold to tenfold in all age groups except 1–4 years
during the period (Table 3).
Over the 12-year interval, the proportion of cases caused
by strains included in the quadrivalent vaccine available in the
United States (A, C, Y, and W135) increased from 28% to 65%
of reported cases (Kruskal-Wallis test; chi square = 57.4; df=3;
p< 0.01). This increase is due in part to the decline in inci-
dence of serogroup B infections and the decline in the number
of cases for which a serogroup could not be determined
(Figure 1).
To assess whether changes in serogroup B and Yincidence
were independent from the changes observed in age, we per-
formed logistic regression analyses. The likelihood of
serogroup Y infection compared with all other serogroups
increased by a factor of 2.47 (99% CI 1.84 to 3.33) for each
successive year group while controlling for age. The likelihood
of serogroup B infections compared with all other serogroups
decreased by a factor of 0.77 (99% CI 0.61 to 0.91) for each
successive year group.
Information about patient outcome was initially available
for 478 (77.7%) of the cases. After the vital records search, one
additional death was identified for a patient with missing out-
come. The overall CFR during 1989–2000 was 16.9% (104
deaths, 615 cases). The CFR varied during the study period,
being lowest in the interval 1992–1994 (14%; 15/109) and
highest in 1989–1991 when 20% (39/196) of the case-patients
died; however, the difference between year groups was not sta-
tistically significant. When we analyzed CFR for each year sep-
arately, we found a surprisingly high CFR of 27% (16/59 cases)
in 1999. 
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Table 2. Meningococcal incidence rates and case-fatality rates by age group and year group, New York City, 1989–2000  
Age group (yr)  1989–1991  1992–1994  1995–1997  1998–2000  1989–2000  Case-fatality rate (%) 
<1  15.9  8.15  7.25  4.23  8.49  13.0 
1–4  2.83  1.10  1.24  0.85  1.50  13.0 
5–14  0.77  0.37  0.61  0.40  0.53  7.8 
15–24  0.99  0.76  0.45  0.72  0.77  10.6 
25–44  0.34  0.21  0.49  0.47  0.38  17.1 
45–64  0.47  0.26  0.61  0.55  0.48  24.4 
>65  0.77  0.45  0.75  0.60  0.64  32.9 
All ages  0.89  0.50  0.69  0.60  0.67  16.9 
aRates are per 100,000. 
Table 3. Annual incidence rates of Neisseria meningitidis, serogroups B and Y, New York City, 1989–2000
a 
1989–1991  1992–1994  1995–1997  1998–2000 
B  Y  B  Y  B  Y  B  Y  Age group 
(yr)  No.  Rate  No.  Rate  No.  Rate  No.  Rate  No.  Rate  No.  Rate  No.  Rate  No.  Rate 
<1   15  5.8  2  0.78  11  4.3  1  0.39  9  2.7  3  0.91  4  1.2  5  1.5 
1–4   13  1.0  0  0  5  0.39  2  0.16  4  0.31  2  0.15  2  0.15  1  0.08 
5–14   3  0.11  1  0.04  4  0.15  0  0  3  0.09  3  0.09  1  0.03  9  0.27 
15–24   9  0.29  1  0.03  5  0.16  4  0.13  2  0.06  3  0.09  3  0.09  7  0.21 
24–44   6  0.08  1  0.01  4  0.05  1  0.01  8  0.10  15  0.19  3  0.04  7  0.09 
45–64   5  0.12  0  0  1  0.02  2  0.04  2  0.04  11  0.22  4  0.08  17  0.33 
≥65   3  0.10  0  0  4  0.14  3  0.10  2  0.07  8  0.28  2  0.07  10  0.36 
All ages  54  0.25  5  0.02  34  0.15  13  0.06  30  0.12  45  0.19  19  0.08  56  0.23 
aRates are per 100,000 and use 1990 and 2000 census figures. CFR increased linearly with age after 5 years of age and
was lowest for those 5–14 years of age (8%) and highest for
>65 years of age (33%) (Table 2). Figure 2 shows CFR by age
category and year group. The CFR also differed by serogroup
and was the highest for serogroup A (44.4%; 4/9), compared to
that observed among serogroups C (22.3%; 25/112), Y (18.5%;
22/119), W (17.9%; 5/28), and B (12.4%; 17/137). However,
the high CFR for serogroup A should be interpreted cautiously
because of the low number of cases in the study period. No sta-
tistically significant difference of CFR between serogroups was
noted (Bonferoni adjustment for multiple comparisons,
p>0.002).
Discussion
Our study has shown that a significant decrease in
meningococcal disease incidence rates occurred at the begin-
ning of the 1990s in New York City, and low incidence rates
were observed throughout the rest of the decade. The decline in
incidence rates are unlikely to have occurred because of
changes in surveillance; no modifications in the diagnostic cri-
teria for meningococcal disease were made, and only passive
surveillance was conducted throughout the entire study period. 
Compared to national surveillance data, the overall inci-
dence rate in New York City during the period was 34% lower
(0.67 vs. 1.02/100,000) (6). Age-specific rates in children <5
years of age have declined both nationally and in New York
City, although the magnitude of the decline in the city has been
greater. Nationally, the rate for patients <1 year of age declined
from 13.5/100,000 in 1989 to 6.79/100,000 in 2000. For chil-
dren 1–4 years of age, the rate declined from 4.18/100,000 to
2.04/100,000 over the same period (6). Much of the decline
occurred during the years 1998–2000. For New York City, the
rates in the <1-year age group declined from 18.6/100,000 in
1989 to 2.72/100,000 in 2000. For the 1–4 year age group, the
rate declined from 4.95/100,000 in 1989 to 0.93/100,000 in
2000. Asimilar trend for New York State (excluding New York
City) has occurred, with overall meningococcal rates dropping
44% (from 1.28/100,000 in 1989 to 0.72/100,000 in 2000) and
the rate <5 years declining 85% (from 8.85/100,000 to
1.29/100,000, unpub. data, New York State Department of
Health, Division of Epidemiology). 
The median age of New York City case-patients was high-
er than that observed in epidemiologic reviews for the United
States and the New England region (2,6). The increase in the
median age of cases from 1989 to 2000 observed in New York
City is predominately due to a decrease in the incidence rates
among young children (1–4 years of age) and infants (<1 year
of age), along with slight increases in rates among adults
(25–64 years of age). This finding of higher median age may be
a result of the greater decline in meningococcal disease seen in
children <5 years of age in New York City compared to the rest
of the United States. 
In accordance with trends observed in other areas of the
United States (2,3), a significant increase in the incidence of
serogroup Y infection occurred in New York City. The median
age of patients with serogroup Y infections in New York City
(30 years) was comparable to that of Connecticut patients (29
years) but greater than that seen in Illinois patients (16 years)
when comparison data from 1989–1996 were used (3).
Serogroup C was responsible for an increasing number of spo-
radic cases and outbreaks in the United States (7) and Canada
(8) in the late 1980s and early 1990s. In New York City, the sin-
gle cluster involving three people in 1997 was caused by
serogroup C infection. The incidence of serogroup C infection
did not change substantially in New York City throughout the
12 years of the study; serotype C infection accounted for 18.2%
of the total number of cases (range per year group 15.6–19.4). 
Serogroup W-135, important worldwide because of the
cases associated with returning pilgrims from Saudi Arabia,
accounted for 4.6% of all cases in New York City from 1989 to
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Figure 1. Distribution of meningococcal serogroups by year group, New
York City, 1989–2000.
Figure 2. Meningococcal case-fatality rate by age category and year
group, New York City, 1989–2000.2000. This association with the pilgrimage to Mecca accounted
for the three cases in New York City caused by serogroup W-
135 reported from January to April in 2000: One patient was a
returning pilgrim, another was a household contact of a return-
ing pilgrim, and the third patient reported having interacted
with returning pilgrims or their families (9).
The incidence rate of serogroup B declined threefold dur-
ing the period of study, and the infection has nearly disappeared
in children <5 years of age in New York City (one case in
1999–2001). The number of serogroup B meningococcal cases
in New York State (excluding New York City) has also
declined, from 10 in 1997 to 3 in 2000 (unpub. data, New York
State Department of Health, Division of Epidemiology). Data
from New Jersey indicate that the number of meningococcal
infections in children <5 years of age has similarly declined,
from 16 in 1995 to 3 in 2000, although the number of serogroup
B cases has remained relatively constant (unpub. data, New
Jersey Department of Health and Human Services). In Oregon,
where an increase in serogroup B meningococcal disease
occurred in the last decade (10), no similar decline in serogroup
B has been seen in children <5 years of age (Frederick Hoesly,
pers. comm.). An interesting discovery is the coincident
increase in the use of Haemophilus influenzae conjugate vac-
cine containing serogroup B meningococcal outer membrane
protein. Private provider vaccine orders received by the
Vaccine for Children program for NYC indicate that the pro-
portion of H. influenzae vaccine containing serogroup B
meningococcal outer membrane protein has risen steadily from
0% in 1994 to 52% in 2000 (unpub. data, Department of
Health, Immunization Program). Comparison Vaccine for
Children data for the public sector are incomplete. Studies con-
ducted by the manufacturer found that immunity to serogroup
B meningococcus was induced by the serogroup B meningo-
coccal outer membrane protein vaccine in a primate animal
model (11) and in children during phase III vaccine trials (Alan
Shaw, pers. comm.). Further epidemiologic and immunologic
research are needed to explore the protective immunity and
potential use of this vaccine for meningococcal serogroup B
disease. 
A significant change occurred in the prevalence of vac-
cine-preventable strains during the period. During the years
1989–1991, only 29.7% (43/145) of the meningococcal infec-
tions that occurred in patients >2 years of age were caused by
vaccine-preventable strains. The proportion of vaccine-pre-
ventable strains increased steadily in each 3-year interval
reaching 66.4% (85/128) in 1998–2000 (chi square for trend;
p<0.01). Currently, the quadrivalent meningococcal polysac-
charide vaccine, the only licensed and approved vaccine in the
United States, provides good efficacy against serogroups A, C,
W-135, and Y infections in older children and adults. The vac-
cine is not routinely recommended for the general population
because of its short duration of protection, poor efficacy in chil-
dren <2 years of age, and the low incidence of meningococcal
infections in the United States (1,12). To overcome the prob-
lems of immunity in young children, conjugate vaccines have
been recently developed and might dramatically improve the
prevention of meningococcal disease because of their greater
efficacy among infants and longer duration of immunity (13).
The conjugate vaccine that is currently licensed in the United
Kingdom only protects against serogroup C infection; its addi-
tion to the routine childhood vaccine schedule in New York
City would have limited impact based on current serogroup
incidence (13). Meningococcal serogroup C accounted for 12%
(3/25) of infections in children <5 years of age and 2% (3/144)
of all meningococcal infections in 1998–2000. During the
entire 12-year period, only one serogroup A meningococcal
infection occurred in a child <5 years of age. To make an
impact on rates of meningococcal disease in New York City
through routine childhood vaccination, a vaccine is needed that
produces good, long-lasting immunity in young children to
serogroups B, C, W-135, and Y.
In contrast with the overall lower incidence rates, the CFR
for 1989–1998 was 16.6% for New York City, compared to
9.3% for the rest of the United States (6). Possible explanations
for this finding include differential reporting of severe cases,
presence of virulent clones in the population, and timely access
of medical care. Additionally, not all public health jurisdictions
include probable cases in their surveillance reports to the
Centers for Disease Control and Prevention, raising the possi-
bility that the national number of deaths is low because of
underreporting of culture-negative fatal cases. A small propor-
tion of cases (5%) in the New York City surveillance database
met the definition for probable cases, suggesting that such
cases may be underreported; however, no statistically signifi-
cant difference existed in deaths by case status (confirmed CFR
= 16.7%; probable CFR = 21.1%; chi square =0.46; p=0.50).
This proportion of probable cases in New York City is compa-
rable to that found in a review of meningococcal disease in
New England for 1993–1998, where 4% of the cases met the
probable case definition and the CFR was 10% (14). The pro-
portion of probable cases and CFR for meningococcal disease
in New Jersey in 1990–2000 were 10.5% and 11.6%, respec-
tively (unpub. data, New Jersey Department of Health and
Senior Services, Infectious and Zoonotic Diseases Program).
An assessment of meningococcal surveillance in New York
State (excluding New York City) found delays but relatively
complete reporting (15). The exceptionally high death rate in
1999 prompted a closer examination of these data. Median age
for the year was 35, higher than median age for any other year
cohort and significantly higher than median age for all other
years (median age excluding 1999 = 21; p=0.013). The propor-
tion of group Y disease was 41%, which also differed signifi-
cantly from the years excluding 1999 (chi square = 19.0,
p<0.01). Further epidemiologic investigation, including molec-
ular typing, is necessary to explain the excess meningococcal
deaths in New York City.
Limitations
A limitation of surveillance-based studies is the bias intro-
duced by underreporting. However, because of the severity of
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most meningococcal disease case-patients are hospitalized, and
the local health department is usually notified in order to track
down close contacts and ensure that they receive antibiotic pro-
phylaxis. A study assessing the completeness of the New York
State surveillance system for meningococcal disease by using
hospital discharge data as the basis for comparison showed that
93% of estimated cases in hospitalized patients in 1991 were
properly reported (15). Hospital practices, such as antibiotic
administration before acquisition of cultures, might render
samples from case-patients culture-negative; however, no evi-
dence suggests that a change in such practice has occurred in
the study interval.
Because our inclusion criteria required a positive bacterial
culture, positive cerebrospinal fluid antigen test, or purpura ful-
minansis, cases that were culture-negative where antigen test-
ing was not available or nonmeningitis cases without purpura
fulminans might have been missed. The use of these inclusion
criteria was important to ensure the validity of the study and
comparability to other jurisdictions but could have slightly
inflated the CFR if fatal cases tend to be reported more often to
the health departments. 
Another limitation was the large proportion of missing
information for outcome (22.1%) that may have underestimat-
ed the CFR. We minimized this problem by performing death
certificate searches using multiple search criteria.
Approximately three quarters of the New York City iso-
lates during the study period were identified by serogroup; this
proportion was similar to that observed in other surveillance-
based studies conducted in the United States (2,3,9). Assuming
that the lack of serogroup information for a proportion of the
cases was not related to problems in identifying any specific
serogroup (i.e., independent from serogroup), bias was unlike-
ly to have been responsible for the observed trends in
serogroup.
The time-trend analysis performed in this study assessed
the presence of epidemiologic trends during the 1990s but not
the factors responsible for them. Therefore, our study was
important in identifying trends, but further studies need to be
conducted to test specific hypotheses about the factors respon-
sible for them. 
National surveillance data used for comparison of rates
and CFR were based on the same case definitions as used in our
study; however, not all jurisdictions follow these definitions.
For example, New York State Department of Health excludes
probable cases, and this variation in surveillance methodology
may affect the national CFR used for comparison.
Conclusions 
In New York City, during the period from 1989 to 2000,
the overall incidence rates of meningococcal disease decreased.
This reduction was more evident in the younger age groups,
and therefore the median age of patients with meningococcal
disease increased. Independent of the changes in the age distri-
bution, the proportion of cases caused by serogroup Y
increased and those caused by serogroup B decreased. The
CFR did not change significantly throughout the study period
and is higher than national figures. The incidence of serogroup
B infections has dramatically declined. Evidence suggests that
this decline may be the unintended result of H. influenzae type
b vaccine use that incorporates the meningococcus serogroup B
outer membrane protein. The implications of this finding
require further research because currently no available vaccine
or satisfactory method exists for controlling outbreaks from
serogroup B.
Understanding trends in meningococcal disease epidemi-
ology is important in redefining appropriate measures of con-
trol and prevention. The identification of groups at high risk
and the distribution of prevailing meningococcal serogroups
will be critical in future decisions and recommendations
regarding the nonepidemic use of meningococcal vaccine.
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